Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Extension of Study GNC-401

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~1. The patient has given written informed consent to participate in the study;~2. Current diagnosis of RMS, based on the McDonald 2017 criteria ;~3. Patients must have completed study GNC-401. Completion is defined as having performed the Week 48 assessments of study GNC 401;~4. Have no clinical (relapses) or MRI signs (≥2 new T2 lesions of \>10 mm diameter) of acute MS disease activity, based on the Week 48 MRI of study GNC 401, or, if yes, been retreated prior to study entry with rituximab;~5. Have a B cell count ≤0.05 x 109 CD19 cells/L (assessed at the end of study GNC 401, or before inclusion in this study GNC 402 (available result from routine clinical practice); if not retreated with rituximab before entering study GNC-402, monthly B-cell count will be executed and retreatment will be considered by the treating physician when B-cells are \>0.05 x 109 CD19 cells/L);~Main exclusion criteria~1. The emergence of any disease diagnosis during the course of study GNC-401 that is not due to MS and could better explain the patient's neurological signs and symptoms;~2. Body weight ≤40 kg;~3. Contraindication to continue rituximab therapy;~4. Has received rituximab less than 12 days prior to study entry;~5. Use of any of the following medications since Week 48 of the GNC 401 study:~   1. Interferon (IFN) β, glatiramer acetate, IV immunoglobulin (IVIG), dimethyl fumarate or teriflunomide;~  2. Natalizumab, mitoxantrone, cladribine, alemtuzumab, cyclophosphamide, systemic cytotoxic therapy, total lymphoid irradiation, and/or bone marrow transplantation;~  3. Highly potent immune modulating therapy, such as: ocrelizumab, ofatumumab, fingolimod, siponimod, ozanimod or anti-cytokine therapy, plasmapheresis or azathioprine;~  4. Any experimental drugs for the treatment of MS;~6. Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or greater lymphopenia (based on Week 48 of study GNC 401);~7. Any major medical or psychiatric disorder that would affect the capacity of the patient to fulfill the requirements of the study, including:~   1. Diagnosis or history of schizophrenia;~  2. Current diagnosis of moderate to severe bipolar disorder, major depressive disorder, major depressive episode, history of suicide attempt, or current suicidal ideation;~  3. Current or past (within the last 2 years) alcohol or drug abuse;~8. History or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure (New York Heart Association \[NYHA\] class 3 or 4);~9. Known inability to undergo an MRI scan;~10. Contraindications to the use of 5% glucose solution for infusion;~11. Inability to follow study instructions, or complete study assessments, as defined by the protocol;~12. Any history of cancer with the exceptions of basal cell carcinoma and/or carcinoma in situ of the cervix, and only if successfully treated by complete surgical resection, with documented clean margins and any medically unstable condition as determined by the Investigator;~13. Pregnant or breastfeeding women;~14. Abnormal liver function tests: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2 times upper limit of normal range (ULN), or conjugated bilirubin \>2 times ULN, or alkaline phosphatase (AP) or gamma-glutamyl transferase (GGT) \>3 times ULN;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Temelimab 18 mg/kg (Type: EXPERIMENTAL): Monthly IV repeated dose
- Temelimab 36 mg/kg (Type: EXPERIMENTAL): Monthly IV repeated dose
- Temelimab 54 mg/kg (Type: EXPERIMENTAL): Monthly IV repeated dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy